Hemophilia is a rare genetic disorder that affects a person's ability to clot blood properly. It is often characterized by prolonged bleeding and difficulty in forming blood clots to stop bleeding after an injury or surgery. Hemophilia is typically caused by a deficiency or abnormality in specific blood clotting proteins known as clotting factors.
Established in 1996, the company is headquartered in Gurugram, India. It operates a network of hospitals, clinics, and diagnostic centers across the country, offering a wide range of medical services, including diagnostic services, surgeries, and treatments for various medical conditions.
Fortis offers genetic testing services to identify mutations or abnormalities in the DMD gene. It also provides diagnostic imaging such as MRI or ultrasound, may be used to assess muscle condition and monitor disease progression.
Khwaja Abdul Hamied established the company in 1935. Its headquarters are located in Mumbai, India. Cipla is involved in the production and distribution of a wide range of pharmaceutical products, including medications and treatments for various medical conditions.
It is engaged in research and development of medications or therapies aimed at managing or alleviating the symptoms of DMD. This could involve the production of drugs that help slow the progression of the disease or provide symptomatic relief.
Headquartered in Leverkusen, Germany, the company was established on August 1st, 1863. It is known for its wide range of products and services in various sectors, including pharmaceuticals, agriculture, and consumer health.
Bayer is involved in the discovery and testing of potential drugs that could slow the progression of the disease or alleviate its symptoms. It also conducts clinical trials to evaluate the safety and efficacy of potential DMD treatments. These trials involve testing new drugs on patients to determine their effects and gather data for regulatory approval.
Headquartered in Cambridge, Massachusetts, United States, the company was established in 1978. Biogen specializes in the development and production of innovative therapies for various neurological and rare diseases.
It is actively engaged in in research and development efforts to discover and develop medications or therapies designed to treat DMD. This could involve the creation of drugs aimed at slowing down the progression of the disease, enhancing muscle function, or addressing specific aspects of the condition.
Established on September 5th, 1998, the company has its headquarters in Rockville, Maryland, United States. Emergent specializes in the development, manufacture, and distribution of biologic and small molecule drugs, vaccines, and therapeutics for a range of medical conditions.
It focuses on the development and production of therapeutics, the diagnostic aspects of DMD, such as genetic testing, clinical evaluation, and muscle biopsies, are primarily conducted by healthcare providers, diagnostic laboratories, and medical professionals. These entities are responsible for diagnosing and monitoring individuals with DMD.
In the vertical of primary hemophilia disease, several key players operate to address the unique healthcare needs of individuals with hemophilia. These players encompass pharmaceutical companies, research institutions, healthcare providers, and patient advocacy groups. They collaborate to develop innovative treatments, conduct clinical trials, and provide specialized care to improve the quality of life for those affected by hemophilia. Together, they work towards advancing our understanding of the disease, enhancing treatment options, and advocating for improved patient care. By their collective efforts, these stakeholders play a vital role in managing primary hemophilia disease and offering hope for those living with this rare and challenging condition.